KRAS degradation averts PDAC chemoresistance

被引：0

作者：

Leonhardt, Laura ^{[1
,2
,3
]}

Hebrok, Matthias ^{[1
,2
,3
,4
,5
,6
]}

机构：

[1] Tech Univ Munich, TUM Sch Med & Hlth, Munich, Germany

[2] Tech Univ Munich, Ctr Organoid Syst, Garching, Germany

[3] Inst Diabet & Organoid Technol, Helmholtz Diabet Ctr, Helmholtz Zentrum Munchen, Neuherberg, Germany

[4] Tech Univ Munich, Munich Inst Biomed Engn MIBE, Munich, Germany

[5] German Ctr Diabet Res DZD, Neuherberg, Germany

[6] Univ Calif San Francisco, Diabet Ctr, Dept Med, San Francisco, CA 94143 USA

来源：

NATURE CANCER | 2024年 / 5卷 / 03期

关键词：

D O I：

10.1038/s43018-023-00708-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Effectively targeting deregulated KRAS signaling remains an unmet clinical need, as current approaches commonly lead to the development of chemoresistance in clinical settings. ADAM9-mediated lysosomal KRAS degradation is now shown to counteract PDAC chemoresistance independently of mutational status.

引用

页码：375 / 377

页数：3

共 50 条

[1] KRAS degradation averts PDAC chemoresistance
Laura Leonhardt
Matthias Hebrok
Nature Cancer, 2024, 5 : 375 - 377
[2] KRAS dosage key in PDAC
Thomas, Hugh
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2018, 15 (03) : 130 - 130
[3] KRAS dosage key in PDAC
Hugh Thomas
Nature Reviews Gastroenterology & Hepatology, 2018, 15 : 130 - 130
[4] Targeting KRAS in PDAC: A New Way to Cure It?
He, Qianyu
Liu, Zuojia
Wang, Jin
CANCERS, 2022, 14 (20)
[5] Identifying synergistic combinations with KRAS inhibition in PDAC
Thege, Fredrik I.
Hoskins, Amber
Woermann, Sonja M.
Maitra, Anirban
CANCER RESEARCH, 2024, 84 (17)
[6] CYP3A5 contributes to PDAC chemoresistance
Hugh Thomas
Nature Reviews Gastroenterology & Hepatology, 2016, 13 (4) : 188 - 188
[7] KRAS as a marker of chemoresistance in lung cancer
Tsao, Ming S.
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S56 - S58
[8] Response and resistance to KRAS inhibition in PDAC mouse models
Abbassi, Laleh
Dilly, Jullien
Yang, Annan
Uribe, Giselle
Parent, Branden
Hennessey, Connor
Kapner, Kevin
Jordan, Alexander
Dasgupta, Shatavisha
Morgado, Micaela
Baslan, Taimour
Qiang, Li
Winter, Peter
Chugh, Seema
Shalek, Alex
Stanger, Ben
Raghavan, Srivastan
Lowe, Scott
Wolpin, Brian
Dougan, Stephanie
Nowak, Jonathan
Aguirre, Andrew
CANCER RESEARCH, 2024, 84 (02)
[9] Targeting KRAS inhibitor resistance by ferroptosis induction in PDAC
Padhye, Aparna
Yu, Qijia
Sindoni, Nicole
Zhang, Huan
Dilly, Julien
Feng, Hanrong
Aguirre, Andrew
Mancias, Joseph
CANCER RESEARCH, 2024, 84 (17)
[10] Impact of KRAS alterations in pancreatic ductal adenocarcinoma (PDAC).
Mehdi, Maahum
Kamgar, Mandana
George, Ben
Szabo, Aniko
Annunzio, Kaitlin
Taylor, Bradley W.
Shreenivas, Aditya Varnam
Chakrabarti, Sakti
Thomas, James P.
Tsai, Susan
Christians, Kathleen K.
Evans, Douglas B.
Clarke, Callisia
Hall, William Adrian
Erickson, Beth
Ahmed, Gulrayz
Thapa, Bicky
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →